COST-EFFECTIVENESS ANALYSIS COMPARING DABIGATRAN AND ADJUSTED-DOSE WARFARIN FOR STROKE PREVENTION IN ATRIAL FIBRILLATION

被引：0
|
作者：
Zhao, Y. [1 ]
Lim, L. [1 ]
Coleman, C., I [2 ]
机构：
[1] Yale Griffin Hosp, Derby, CT USA
[2] Univ Connecticut, Sch Pharm, Storrs, CT USA
来源：
VALUE IN HEALTH | 2011年 / 14卷 / 03期
关键词：
D O I：
10.1016/j.jval.2011.02.237
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A41 / A41
页数：1
相关论文
共 50 条
  • [1] Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation
    Freeman, James V.
    Zhu, Ruo P.
    Owens, Douglas K.
    Garber, Alan M.
    Hutton, David W.
    Go, Alan S.
    Wang, Paul J.
    Turakhia, Mintu P.
    ANNALS OF INTERNAL MEDICINE, 2011, 154 (01) : 1 - U129
  • [2] Cost-Effectiveness of High-Dose Edoxaban Compared with Adjusted-Dose Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation Patients
    Nguyen, Elaine
    Egri, Florence
    Mearns, Elizabeth S.
    White, Charles M.
    Coleman, Craig I.
    PHARMACOTHERAPY, 2016, 36 (05): : 488 - 495
  • [3] Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation
    Harrington, Amanda R.
    Armstrong, Edward P.
    Nolan, Paul E., Jr.
    Malone, Daniel C.
    STROKE, 2013, 44 (06) : 1676 - +
  • [4] Cost-effectiveness analysis of dabigatran, rivaroxaban and warfarin in the prevention of stroke in patients with atrial fibrillation in China
    Wei, Hongtao
    Cui, Can
    Cui, Xiangli
    Liu, Yi
    Li, Dandan
    BMC HEALTH SERVICES RESEARCH, 2021, 21 (01)
  • [5] Cost-Effectiveness Analysis of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation in Taiwan
    Chieh-Yu Liu
    Hui-Chun Chen
    Clinical Drug Investigation, 2017, 37 : 285 - 293
  • [6] Cost-Effectiveness Analysis of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation in Taiwan
    Liu, Chieh-Yu
    Chen, Hui-Chun
    CLINICAL DRUG INVESTIGATION, 2017, 37 (03) : 285 - 293
  • [7] COST-EFFECTIVENESS ANALYSIS OF DABIGATRAN COMPARED TO WARFARIN FOR STROKE PREVENTION IN ATRIAL FIBRILLATION IN A MEDICARE POPULATION
    Ward, M. A.
    Biddle, A. K.
    VALUE IN HEALTH, 2012, 15 (04) : A121 - A121
  • [8] Cost-effectiveness of high-dose edoxaban compared to adjusted-dose warfarin for prevention of stroke and systemic embolism in non-valvular atrial fibrillation
    Mearns, E.
    Doleh, Y.
    Coleman, C. I.
    EUROPEAN HEART JOURNAL, 2014, 35 : 896 - 896
  • [9] Cost-effectiveness of Dabigatran and Rivaroxaban Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation
    Wang, Ye
    Xie, Feng
    Kong, Ming Chai
    Lee, Lai Heng
    Ng, Heng Joo
    Ko, Yu
    CARDIOVASCULAR DRUGS AND THERAPY, 2014, 28 (06) : 575 - 585
  • [10] The budget impact of left atrial appendage closure compared with adjusted-dose warfarin and dabigatran etexilate for stroke prevention in atrial fibrillation
    Amorosi, Stacey L.
    Armstrong, Shannon
    Da Deppo, Lisa
    Garfield, Susan
    Stein, Kenneth
    EUROPACE, 2014, 16 (08): : 1131 - 1136
12345